Summary Background Keverprazan is a novel potassium‐competitive acid blocker (P‐CAB) with a strong acid‐suppressive capacity that may provide clinical benefit in acid‐related diseases. Aims This study aimed to explore the non‐inferior efficacy and safety of keverprazan to lansoprazole in treating erosive oesophagitis (EO). Methods This was a phase III, randomised, double‐blind multicentre study. Patients were randomised to receive keverprazan 20 mg once daily or lansoprazole 30 mg once daily for 4–8 weeks. EO healing rates and adverse events (AEs) were compared between the keverprazan group and the lansoprazole group. Results A total of 238 patients comprised the full analysis set (FAS) while 221 patients comprised the per‐protocol set (PPS). For FAS analysis, the EO healing rates at week 8 were 95.8% (114/119) and 89.9% (107/119) for keverprazan and lansoprazole respectively. For PPS analysis, the EO healing rates at week 8 were 99.1% (110/111) and 92.7% (102/110) for keverprazan and lansoprazole respectively. Non‐inferiority of keverprazan compared with lansoprazole according to EO healing rates at 8 weeks was demonstrated in both FAS (difference: 5.8% [95% CI: −0.6% to 12.3%]; p = 0.081) and PPS (difference: 6.1% [95% CI: 1.1%–11.2%]; p = 0.018) analysis. Drug‐related AEs were reported in 34.5% (41/119) patients of the keverprazan group and 25.2% (30/119) patients of the lansoprazole group with no significant difference (p = 0.156). No severe AE happened in the keverprazan group. Conclusions This study demonstrated the non‐inferior efficacy of keverprazan to lansoprazole in treating EO. The incidences of drug‐related AEs were comparable between keverprazan and lansoprazole.

No abstract

No abstract

Purpose This study aimed to discover novel prognostic biomarkers for colon adenocarcinoma (COAD) based on ferroptosis-related lncRNA analysis. Methods The RNA-seq data and clinical samples were obtained from TCGA database. Ferroptosis-related genes used were downloaded from the GSEA database. We screened ferroptosis-related lncRNAs with correlation coefficient \(\left|R\right|\)>0.3 and P < 0.001. By Cox analysis and LASSO regression, the prognostic ferroptosis-related lncRNAs were identified and their risk scores were obtained. Combining risk scores and clinical features, a nomogram was constructed and was validated by C-index, AUC and calibration diagram. Results An eight-lncRNAs signature was built up, comprising ZEB1-AS1, AL354993.2, LINC02381, AP001505.1, NCK1-DT, CD27-AS1, AC068580.3 and SNHG16. The AUC of ROC curve was 0.737 in predicting 3-years survival and 0.785 in predicting 5-years survival and C-index was 0.795 in the prognostic model. Conclusions ZEB1-AS1, AL354993.2, LINC02381, AP001505.1, NCK1-DT, CD27-AS1 and AC068580.3 may be negative factors while SNHG16 may be a positive factor for the survival time of COAD patients. The eight ferroptosis-related lncRNA signature has a certain capability in predicting the overall survival of patients with COAD and these selected lncRNAs may serve as novel prognostic biomarkers.